Processing

Please wait...

Settings

Settings

1. WO2000042044 - NOVEL ARALKYL AMINES OF SPIROFUROPYRIDINES USEFUL IN THERAPY

Publication Number WO/2000/042044
Publication Date 20.07.2000
International Application No. PCT/SE1999/002478
International Filing Date 23.12.1999
Chapter 2 Demand Filed 19.07.2000
IPC
C07D 491/22 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
22in which the condensed system contains four or more hetero rings
CPC
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
C07D 491/22
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
491Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
22in which the condensed system contains four or more hetero rings
Applicants
  • ASTRAZENECA AB [SE/SE]; S-151 85 Södertälje, SE (AllExceptUS)
  • LOCH, James, III [US/US]; US (UsOnly)
  • MULLEN, George [US/US]; US (UsOnly)
  • PHILLIPS, Eifion [GB/US]; US (UsOnly)
Inventors
  • LOCH, James, III; US
  • MULLEN, George; US
  • PHILLIPS, Eifion; US
Agents
  • ASTRAZENECA AB; Intellectual Property, Patents S-151 85 Södertälje, SE
Priority Data
9900100-015.01.1999SE
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NOVEL ARALKYL AMINES OF SPIROFUROPYRIDINES USEFUL IN THERAPY
(FR) NOUVELLES ARALKYLAMINES DE SPIROFUROPYRIDINES UTILES EN THERAPIE
Abstract
(EN)
A compound of formula (I), wherein NRR1 is attached at the 5- or 6-position of the furopyridine ring; R is hydrogen, C1-C4 alkyl, or COR2; R1 is (CH2)nAr, CH2CH=CHAr, or CH2C$m(Z)CAr; n is 0 to 3; A is N or NO; Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur, any of which may optionally be substituted with one to two substituents independently selected from: halogen, trifluoromethyl, or C1-C4 alkyl; R2 is hydrogen, C1-C4 alkyl, C1-C4 alkoxy or phenyl ring optionally substituted with one to three of the following substituents: halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, OH; OC1-C4 alkyl, CO2R5, -CN, -NO2, -NR3R4, or -CF3; R3, R4 and R5 may be hydrogen, C1-C4 alkyl, or phenyl ring optionally substituted with one to three of the following substituents: halogen, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl, OH; OC1-C4 alkyl, -CN, -NO2, or -CF3; and enantiomers thereof, and pharmaceutically acceptable salts thereof, processes for preparing them, composition containing them, and their use in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders.
(FR)
La présente invention porte sur un composé de formule (I) dans laquelle NRR1 est attaché à la position 5 ou 6 de l'anneau furopyridine; R représente hydrogène, alkyle C1-C4 ou COR2; R1 représente (CH2)nAr, CH2CH=CHAr ou CH2C$m(Z)CAr; n est compris entre 0 et 3; A représente N ou NO; Ar représente un anneau aromatique ou hétéroaromatique formé de 5 ou 6 constituants qui contient entre zéro et quatre atomes d'azote, entre zéro et un atome d'oxygène et entre zéro et un atome de soufre, ou bien un système d'anneau aromatique ou hétéroaromatique fusionné à 8, 9 ou 10 constituants, contenant entre zéro et un atome d'oxygène et entre zéro et un atome de soufre dont un quelconque peut être facultativement substitué par un ou deux substituants indépendamment sélectionnés entre halogène, trifluorométhyle ou alkyle C1-C4; R2 représente hydrogène, alkyle C1-C4, alcoxy C1-C4 ou un anneau phényle facultativement substitué par un à trois des substituants suivants: halogène, alkyle C1-C4, alcényle C2-C4, alcynyle C2-C4, OH; alkyle OC1-C4, CO2R5, -CN, -NO2, -NR3R4 ou -CF3; R3, R4 et R5 peuvent représenter hydrogène, alkyle C1-C4 ou un anneau phényle facultativement substitué par un, deux ou trois substituants parmi les suivants: halogène, alkyle C1-C4, alcényle C2-C4, alcynyle C2-C4, OH; alkyle OC1-C4, -CN, -NO2 ou -CF3. La présente invention concerne ces composés, leurs énantiomères ainsi que leurs sels pharmaceutiquement acceptables, des procédés de préparations de ces derniers, une composition les contenant et leur utilisation en thérapie, plus particulièrement dans le traitement ou la prévention des troubles psychotiques et des troubles liés à la diminution des capacités intellectuelles.
Also published as
CZPV2001-2554
ININ/PCT/2001/00806/MUM
IS6000
NO20013478
NZ512733
SK200100993
SK9932001
TR2001/02042
ZA200105527
Latest bibliographic data on file with the International Bureau